A recent press release indicates that CanaQuest Medical Corp has filed a cannabis patent for a THC formula. CanaQuest is recognized as a company with a unique line of nutraceutical products that utilize cannabis and botanical oil extracts.
According to the press release, the company has filed an “International Cannabis/Botanical Patent which stems from its sponsored research program at Western University in London, Ontario, Canada.” The patented formula is “Mentabinol,” which is used to treat various psychiatric disorders. The product is formulated using “BX,” a Food Grade Botanical Extract. It also includes extracted THC oil from the MJ plant.
Mentabinol has been through pre-trials at Western University. The press release reveals that the substance has been demonstrated to reverse depression-like and schizophrenia-related symptom effects, complete blockage of memory impairment, complete blockage of hyperactive activity, and complete blockage of gene vulnerability.
The team making the discovery was led by Dr. Steven Laviolette, who stated in the press release,
“We are very excited by this unique discovery. Reducing the negative side effects of THC is an important step forward in developing more effective cannabinoid therapeutics”.
He continued, “We are continuing to work out the precise molecular mechanisms underlying the therapeutic modes of action for several unique cannabinoid formulations. These research projects are identifying safer and clinically superior cannabinoid formulations aimed at treating the symptoms of various psychiatric disorders, while eliminating the negative side effects associated with traditional marijuana formats. Our research projects have identified safer and clinically superior cannabinoid formulations aimed at treating the symptoms of various mental disorders.”
CanaQuest co-founder and president also added, “Our Patent is the foundation for real scientifically backed medical cannabis treatment for patients in need.”